Education Steering Committee:
Mark A. Frye, MD
Professor of Psychiatry
Department of Psychiatry & Psychology
Director, Mayo Mood Clinic & Research Program
Terence A. Ketter, MD
Professor, Department of Psychiatry and Behavioral Sciences
Chief, Bipolar Disorders Clinic
Stanford University School of Medicine
Melissa P. DelBello, MD
Co-Director, Division of Bipolar Disorders Research
Vice-Chair Clinical Research Department of Psychiatry
Associate Professor of Psychiatry, Pediatrics and Psychology
University of Cincinnati College of Medicine
Director, Research Training and Education
Division of Child Psychiatry
Cincinnati Children’s Hospital Medical Center
S. Nassir Ghaemi MD, MPH (Online Presenter)
Professor of Psychiatry
Director, Mood Disorders and Psychopharmacology Research Programs
Tufts Medical Center
David J. Muzina, MD
Director, Center for Mood Disorders Treatment & Research
Associate Professor of Medicine
Cleveland Clinic Neurological Institute – Psychiatry & Psychology
Martha Sajatovic, MD
Professor, Department of Psychiatry
Case Western Reserve University School of Medicine
Director, Geropsychiatry Program
University Hospitals of Cleveland
Bipolar disorder is a severe, biphasic chronic mood disorder that affects more than 2 million people in the United States. Proper diagnosis and management of bipolar disorder is essential for optimal patient outcomes; however, clinicians face numerous barriers in treating this population. Up to 70% of affected individuals are initially misdiagnosed with other psychiatric disorders, such as unipolar depression, anxiety, or schizophrenia. Along with marked functional and psychosocial impairment, bipolar disorder is also associated with a high prevalence of medical and psychiatric comorbidity, as well as a lifetime suicide risk of 15%. Appropriate pharmacotherapy is a key component of successful treatment, but many patients with bipolar disorder have difficulty adhering to a prescribed medication regimen.
This online activity was recorded at Poplar Springs Hospital Center in Petersburg, VA on February 4, 2009. If you received CME credit for that presentation you are not eligible to receive credit for this online presentation. Program Developer/Facilitator
. Target Audience
This educational activity, developed by experts in psychiatry, is designed for physicians involved in the care of patients with bipolar disorder.
Upon completion of this educational activity, the participant should be able to:
Outline the key clinical distinctions that separate unipolar depression from bipolar depression.
Define ways to identify and manage anxiety, alcohol, and substance use disorder comorbidities that are related to bipolar disorder.
Assess the efficacy of mood-stabilizing and second-generation antipsychotic agents that treat acute mania.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents used in the diagnosis and management of bipolar disorder. Some uses may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Melissa P. DelBello, MD discloses that she has received research support from AstraZeneca, Eli Lilly, Janssen, Pfizer, Shire, and Somerset; is a member of speakers’ bureaus for AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, and Pfizer; and is a consultant for AstraZeneca, Eli Lilly, France Foundation, GlaxoSmithKline, and Pfizer.
Mark A. Frye, MD discloses that he is a consultant for Abbott, Bristol-Myers Squibb, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Organon, and Otsuka.
S. Nassir Ghaemi, MD, MPH discloses that he has received research support from GlaxoSmithKline, and Pfizer; is a member of speakers’ bureaus for Abbott, AstraZeneca, GlaxoSmithKline, Janssen, and Pfizer; and a member of advisory committees for Abbott, GlaxoSmithKline, Janssen, Pfizer, and Shire.
Terence A. Ketter, MD discloses that he has received research support from Abbott, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, GlaxoSmithKline, Pfizer, Repligen, and Wyeth; is a member of speakers’ bureaus for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and Otsuka; is a consultant for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Jazz, Novartis, Organon, Solvay, Valeant, Vanda, and Wyeth; and his spouse is employed by Johnson & Johnson.
David J. Muzina, MD discloses that he has received research support from Abbott, Eli Lilly, GlaxoSmithKline, and Repligen; and is a member of speakers’ bureaus for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Sepracor, and Wyeth.
Martha Sajatovic, MD discloses that she has received research support from AstraZeneca and GlaxoSmithKline; and is a consultant for AstraZeneca and GlaxoSmithKline. Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
To receive credit, please read the monograph in its entirety and complete the online post-test and program evaluation. Credit will be awarded for a score of 70% or better, and a statement of credit will be available immediately. There is no charge for CME credit. This activity should take approximately 60 minutes to complete.
Commercial Support Statements
This activity is supported through an educational grant from Eli Lilly and Company.
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon at the bottom of this screen. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next main menu screen will permit you to check for or download the Flash player required to run this program. Clicking on "Click here to start the Virtual Meeting" on this screen will begin the program presentation. The menu at the top of the presentation screen will allow you to view the question and answer segment, the reference list, an appendix and the CME post-test and evaluation. The program will take approximately 45 minutes to complete.
Upon completion of the program, click on the post-test button to access the post-test and program evaluation.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME certificate.
©2009 Medical Communications Media, Inc. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational program are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Eli Lilly and Company. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.